Short answer: On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The policy covers one salt form and set routes for each, and applies only when ten conditions are met, including a patient-specific prescription and one peptide per product. It does not put any of them on FDA's 503A bulks list and does not make them FDA approved. Comments on docket HHS-OASH-2026-0496 close on November 13, 2026.
All facts below come from the Federal Register notice, the HHS policy and its Appendix B, read on November 11, 2026. This is a summary of a government document, not legal or medical advice.
What HHS published, and when
The Federal Register notice (FR Doc. 2026-22192, 91 FR 68526) was filed on October 28, 2026 and published on October 30, 2026. It is signed by HHS Secretary Robert F. Kennedy, Jr. and announces a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The notice says the draft "is not binding on HHS or the public" and that HHS may revisit it if "a safety signal or product quality issue arises."
Comments go to regulations.gov on docket HHS-OASH-2026-0496. The notice gives two weeks from publication, and the docket lists the comment period as ending on November 13, 2026.
Note the sender. This came from the HHS Secretary's office, not from FDA. In July 2026, FDA's own staff recommended against adding all seven peptides it reviewed to the 503A bulks list (see our post on that meeting).
The six peptides, forms and routes
The policy lists six peptides in Appendix A. Appendix B then limits each one to a single form and set routes:
| Peptide | Form covered | Routes covered |
|---|---|---|
| BPC-157 | Acetate | Under the skin, into muscle, by mouth, on the skin |
| TB-500 | Acetate | Under the skin or into muscle |
| Epitalon | Acetate | Under the skin or into muscle, in intermittent courses |
| Semax | Free base | In the nose |
| KPV | Acetate | On the skin and by mouth |
| MOTS-c | Acetate | Under the skin or into muscle |
So the policy does not cover, for example, injected KPV or injected semax. Appendix B also fixes each peptide's identity: amino acid sequence, molecular formula and molecular weight.
The ten conditions
HHS says it does not intend to act only "when all of the following circumstances are present." In plain words:
- The peptide is on the Appendix A list.
- It matches the identity and routes in Appendix B.
- The raw ingredient comes from an FDA-registered facility, with a valid certificate of analysis showing tests for identity, purity, potency and contaminants such as endotoxins and heavy metals. Our COA guide explains those tests.
- The original maker is FDA-registered, follows manufacturing rules (CGMP) and is named, with its location, on the certificate.
- The compounder reports products made, serious adverse events and quality problems to FDA's MedWatch program and to the states involved, and the patient's label explains how to report problems.
- The label says: "This is a compounded drug product. Not for resale."
- Each product contains only one listed peptide. No blends.
- For any oral form, the compounder keeps records showing the formula reaches "an adequate level of oral bioavailability in humans."
- The only device allowed is an FDA 510(k)-cleared syringe.
- Everything else in the law still applies, including clean conditions and a valid patient-specific prescription.
Why HHS says it acted
The policy says it aims to discourage use of "research-use-only peptides supplied by foreign manufacturers" and to give patients "a more controlled alternative." It cites the July 2026 advisory committee and data on how often the peptides are used.
Appendix B gives a three-part reason for each peptide. The common threads: use is now documented, and newer certificates of analysis from FDA-registered sites fill testing gaps FDA staff had flagged. For TB-500, epitalon, semax and KPV, HHS describes FDA's safety concerns as inferential, mechanistic or based on missing information, rather than on observed harm. Appendix B also states that the advisory committee voted in favor of each of the six.
Where FDA's own review landed
FDA's July 2026 briefing documents found that "a balancing of the criteria weighs against" listing each peptide. For MOTS-c, for example, FDA's review said it was "particularly concerned about the lack of human data" and found no clinical studies. Appendix B instead points to newer documents; for BPC-157 it cites "evidence that was not before" FDA's drug center. Our MOTS-c trials post, BPC-157 evidence post and TB-500 post cover the human data.
What the policy does not do
- It is not a listing. The six are still not on the 503A bulks list. The notice says "FDA's future rulemakings may propose adding some or all." The policy runs until each peptide "is addressed in a final rule."
- It is not an approval. The notice repeats that compounded drugs "are not FDA-approved," so FDA has not reviewed their safety, effectiveness or quality.
- It does not cover research-use-only sellers. It applies to pharmacies, federal facilities and physicians filling a prescription. FDA has kept sending warning letters to online sellers in 2026; see our count of those letters.
- It does not cover blends or pens. One peptide per product, and only a 510(k)-cleared syringe as the device.
- It does not cover the other withdrawn peptides, such as GHK-Cu, ipamorelin or CJC-1295, which are not in Appendix A.
What this means for you
- Talk to your clinician before starting, changing or stopping any of these. Human data on all six is thin, and this page gives no dosing.
- A product made under this policy should carry the "compounded drug product" label line and come with a prescription in your name.
- If something goes wrong, you can report it yourself to FDA MedWatch.
- Keep the pharmacy label, lot number and certificate of analysis. Policies like this can change, and those records are what you and your clinician will need.
Frequently asked questions
Did HHS legalize BPC-157 in 2026?+
Which peptides are in the HHS policy?+
When do comments on the HHS peptide policy close?+
Can a pharmacy make a peptide blend under the HHS policy?+
Does the HHS policy cover research use only peptides sold online?+
Is the HHS peptide policy permanent?+
Related reading
- The FDA's 2026 peptide compounding decisions
- FDA peptide warning letters (2026)
- MOTS-c human trials (2026)
- BPC-157 in humans: what the evidence shows
- TB-500 and thymosin beta-4: the evidence
- What "research use only" means
- How to read a peptide COA
- Compound library
Questions about the app? See the help center or join the Dose Track community.
Sources
Every fact in this article comes from one of these sources, checked on November 11, 2026. This article is for education. It is not medical or legal advice, and nothing here is a dose recommendation.
- Federal Register. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket No. HHS-OASH-2026-0496, FR Doc. 2026-22192, 91 FR 68526, October 30, 2026. federalregister.gov · PDF
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy and Appendix A). hhs.gov
- U.S. Department of Health and Human Services. Appendix B: Peptide Identities and Justifications for Placement of Peptide Bulk Drug Substances. hhs.gov · combined version linked from the notice: hhs.gov
- Regulations.gov. Docket HHS-OASH-2026-0496 (comment period dates). regulations.gov
- U.S. Food and Drug Administration. FDA Briefing Document, MOTS-c-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov/media/193347/download
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov